Log In
Print this Print this

MN-246 (formerly TT-138)

  Manage Alerts
Collapse Summary General Information
Company Mitsubishi Tanabe Pharma Corp.
DescriptionSelectively stimulates adrenergic receptor beta 3 in urinary bladder smooth muscles
Molecular Target Adrenergic receptor beta 3 (ADRB3)
Mechanism of ActionAdrenergic receptor beta 3 (ADRB3) agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationIncontinence
Indication DetailsTreat pollakiuria; Treat urinary incontinence
Regulatory Designation
PartnerMediciNova Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today